Pfizer Discontinues A Phase 3 Trial Of Figitumumab In Non-Small Cell Lung Cancer (NSCLC) For Futility
Business Wire
December 29, 2009 05:01 PM Eastern Time
Findings to be Incorporated into Ongoing Clinical Trial Program
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients...
The American Journal of Hematology/Oncology
Tasheema Prince
December 11, 2009
Women with advanced epithelial ovarian cancer survive longer with dose-dense treatments of paclitaxel compared to conventional regimens, according to results of a study published in The Lancet (2009;347[9698]:1331-1338).
In the press release announcing the findings, the authors explained that paclitaxel and carboplatin given every 3 weeks is currently considered standard first-line...
The intake of patients for a phase III clinical trial of a lung-cancer drug has been suspended after the group being treated suffered more deaths than those who used established medicines.
US pharmaceutical giant Pfizer decided not to expand the trial of its figitumumab product after its test group suffered more adverse events, including fatalities, The Wall Street Journal reported.
TORONTO (Reuters) - Oncolytics Biotech Inc said on Friday it has reached an agreement with the U.S. Food and Drug Administration on the design of a late-stage trial for its cancer treatment, sending its shares to a three-year high.
The small Canadian drugmaker said the Phase 3 trial for Reolysin will study the effectiveness of the treatment in combination with paclitaxel and carboplatin in patients with head and...
* Drug tested in combination with carboplatin, paclitaxel
* Shares up 33 percent in after-market trade
Oct 1 (Reuters) - Telik Inc (TELK.O) said its drug candidate Telcyta showed positive results in an early-stage trial as a combination therapy for non-small cell lung cancer patients, sending its shares up as much as 33 percent in after-market trade.
Telcyta, in combination with carboplatin and paclitaxel chemotherapy...
